SCHEMBL4831282

SCHEMBL4831282

O=C(Nc1cc(OCCCO/N=C/c2ccc(-c3ccccc3)cc2)ccc1C(=O)O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF2BP2 Q9Y6M1 1/20 0.55
PLK1 P53350 2/20 0.44
KCNK2 O95069 2/20 0.43
KCNK10 P57789 2/20 0.43
HDAC1 Q13547 3/20 0.42
HDAC2 Q92769 3/20 0.42
DHODH Q02127 1/20 0.41
ACLY P53396 2/20 0.41
MCHR1 Q99705 1/20 0.40
MEN1 O00255 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KMT2A Q03164 2/20 0.40
MITF O75030 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
POLB P06746 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GALK1 P51570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831288 1.00 IGF2BP2 (0.55) IGF2BP2PLK1KCNK2KCNK10HDAC1
SCHEMBL4836420 0.94 IGF2BP2 (0.49) IGF2BP2PLK1KCNK2KCNK10HDAC1
SCHEMBL4836430 0.94 IGF2BP2 (0.49) IGF2BP2PLK1KCNK2KCNK10HDAC1
SCHEMBL4825688 0.92 ACLY (0.47) IGF2BP2PLK1KCNK2KCNK10HDAC1
SCHEMBL4825675 0.92 ACLY (0.47) IGF2BP2PLK1KCNK2KCNK10HDAC1
SCHEMBL4827015 0.92 CTDSP1 (0.46) IGF2BP2PLK1KCNK2KCNK10MEN1
SCHEMBL4827028 0.92 CTDSP1 (0.46) IGF2BP2PLK1KCNK2KCNK10MEN1
SCHEMBL4833874 0.89 PLK1 (0.47) IGF2BP2PLK1KCNK2KCNK10HDAC1
SCHEMBL4833858 0.89 PLK1 (0.47) IGF2BP2PLK1KCNK2KCNK10HDAC1
SCHEMBL4830825 0.88 ACLY (0.53) IGF2BP2PLK1KCNK2KCNK10HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US claimed
US-20080293790-A1 SUBSTITUTED ARYL OXIMES WYETH (US) 2008-11-27 US disclosed
US-7420083-B2 Substituted aryloximes WYETH (US) 2008-09-02 US disclosed
US-20050070584-A1 Substituted aryloximes WYETH (US) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070584-A1 Substituted aryloximes AHR, NQO1, AOX1 IGF2BP2 3245/4885PLK1 3639/4885KCNK2 3034/4885
US-20080293790-A1 SUBSTITUTED ARYL OXIMES HCCS, AOX1, TET2 IGF2BP2 3268/4885PLK1 4185/4885KCNK2 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.